🎉 M&A multiples are live!
Check it out!

Ventyx Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ventyx Biosciences and similar public comparables like Pharming, Benevolent AI, and Julphar.

Ventyx Biosciences Overview

About Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.


Founded

2018

HQ

United States of America
Employees

82

Website

ventyxbio.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$128M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Ventyx Biosciences Financials

Ventyx Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Ventyx Biosciences achieved revenue of n/a and an EBITDA of -$147M.

Ventyx Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Ventyx Biosciences valuation multiples based on analyst estimates

Ventyx Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$207M -$147M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$108M -$193M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Ventyx Biosciences Stock Performance

As of April 15, 2025, Ventyx Biosciences's stock price is $1.

Ventyx Biosciences has current market cap of $78.2M, and EV of -$128M.

See Ventyx Biosciences trading valuation data

Ventyx Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$128M $78.2M XXX XXX XXX XXX $-2.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Ventyx Biosciences Valuation Multiples

As of April 15, 2025, Ventyx Biosciences has market cap of $78.2M and EV of -$128M.

Ventyx Biosciences's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Ventyx Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Ventyx Biosciences and 10K+ public comps

Ventyx Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$128M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.9x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Ventyx Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Ventyx Biosciences Valuation Multiples

Ventyx Biosciences's NTM/LTM revenue growth is Infinity%

Ventyx Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.8M for the same period.

Over next 12 months, Ventyx Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Ventyx Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Ventyx Biosciences and other 10K+ public comps

Ventyx Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -29% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Ventyx Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Ventyx Biosciences M&A and Investment Activity

Ventyx Biosciences acquired  XXX companies to date.

Last acquisition by Ventyx Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Ventyx Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Ventyx Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Ventyx Biosciences

When was Ventyx Biosciences founded? Ventyx Biosciences was founded in 2018.
Where is Ventyx Biosciences headquartered? Ventyx Biosciences is headquartered in United States of America.
How many employees does Ventyx Biosciences have? As of today, Ventyx Biosciences has 82 employees.
Who is the CEO of Ventyx Biosciences? Ventyx Biosciences's CEO is Dr. Raju S. Mohan, PhD.
Is Ventyx Biosciences publicy listed? Yes, Ventyx Biosciences is a public company listed on NAS.
What is the stock symbol of Ventyx Biosciences? Ventyx Biosciences trades under VTYX ticker.
When did Ventyx Biosciences go public? Ventyx Biosciences went public in 2021.
Who are competitors of Ventyx Biosciences? Similar companies to Ventyx Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Ventyx Biosciences? Ventyx Biosciences's current market cap is $78.2M
Is Ventyx Biosciences profitable? Yes, Ventyx Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.